Skip to main content
Clinical Trials/NCT02404818
NCT02404818
Completed
Not Applicable

UFPTI 1431 - HL02: Investigating Early Markers of Radiation-Induced Cardiac Injury in Hodgkin Lymphoma Survivors Treated With Either Photon or Proton Radiation

University of Florida1 site in 1 country5 target enrollmentApril 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hodgkin's Lymphoma
Sponsor
University of Florida
Enrollment
5
Locations
1
Primary Endpoint
Cardiac Abnormalities As Measured By Cardiac MRI
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The purpose of this study is to evaluate if radiation and chemotherapy treatment cause cardiac abnormalities among survivors of Hodgkin's lymphoma.

Registry
clinicaltrials.gov
Start Date
April 2015
End Date
April 14, 2021
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Completed radiation and chemotherapy treatment for Hodgkin lymphoma involving the mediastinum.
  • Patient must be ≥ 18 years at time of consent.

Exclusion Criteria

  • Pregnant women at time of Cardiac MRI
  • Contraindications to Cardiac MRI (contrast allergy, metal implants, medical devices)
  • Glomerular filtration rate (GFR) \< 30, unless approved by Radiologist (UF Health Jacksonville Radiology Policy: Administration of Gadolinium-Based Contrast Agents).

Outcomes

Primary Outcomes

Cardiac Abnormalities As Measured By Cardiac MRI

Time Frame: Day 1

Cardiac Abnormalities As Measured By Echocardiogram

Time Frame: Day 1

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Characterizing Chemo-Radiotherapy Treatment-Related Cardiac ChangesClinical Stage 0 Esophageal Adenocarcinoma AJCC V8Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC V8Clinical Stage I Esophageal Adenocarcinoma AJCC V8Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC V8Clinical Stage II Esophageal Adenocarcinoma AJCC V8Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC V8Clinical Stage IIA Esophageal Adenocarcinoma AJCC V8Clinical Stage IIB Esophageal Adenocarcinoma AJCC V8Clinical Stage III Esophageal Adenocarcinoma AJCC V8Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC V8Localized Esophageal CarcinomaLocalized Lung CarcinomaPathologic Stage 0 Esophageal Adenocarcinoma AJCC V8Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC V8Pathologic Stage I Esophageal Adenocarcinoma AJCC V8Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC V8Pathologic Stage IA Esophageal Adenocarcinoma AJCC V8Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC V8Pathologic Stage IB Esophageal Adenocarcinoma AJCC V8Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC V8Pathologic Stage IC Esophageal Adenocarcinoma AJCC V8Pathologic Stage II Esophageal Adenocarcinoma AJCC V8Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC V8Pathologic Stage IIA Esophageal Adenocarcinoma AJCC V8Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC V8Pathologic Stage IIB Esophageal Adenocarcinoma AJCC V8Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC V8Pathologic Stage III Esophageal Adenocarcinoma AJCC V8Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC V8Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC V8Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC V8Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC V8Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC V8Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC V8Postneoadjuvant Therapy Stage I Esophageal Squamous Cell Carcinoma AJCC V8Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC V8Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma AJCC V8Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC V8Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC V8Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC V8Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC V8Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC V8Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC V8Stage 0 Lung Cancer AJCC V8Stage I Lung Cancer AJCC V8Stage IA1 Lung Cancer AJCC V8Stage IA2 Lung Cancer AJCC V8Stage IA3 Lung Cancer AJCC V8Stage IB Lung Cancer AJCC V8Stage II Lung Cancer AJCC V8Stage IIA Lung Cancer AJCC V8Stage IIB Lung Cancer AJCC V8Stage III Lung Cancer AJCC V8Stage IIIA Lung Cancer AJCC V8Stage IIIB Lung Cancer AJCC V8Stage IIIC Lung Cancer AJCC V8Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8Clinical Stage I Esophageal Adenocarcinoma AJCC v8Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8Clinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8Pathologic Stage 0 Esophageal Adenocarcinoma AJCC v8Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8Pathologic Stage I Esophageal Adenocarcinoma AJCC v8Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8Pathologic Stage IA Esophageal Adenocarcinoma AJCC v8Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8Pathologic Stage II Esophageal Adenocarcinoma AJCC v8Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8Pathologic Stage III Esophageal Adenocarcinoma AJCC v8Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage I Esophageal Squamous Cell Carcinoma AJCC v8Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma AJCC v8Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8Stage 0 Lung Cancer AJCC v8Stage I Lung Cancer AJCC v8Stage IA1 Lung Cancer AJCC v8Stage IA2 Lung Cancer AJCC v8Stage IA3 Lung Cancer AJCC v8Stage IB Lung Cancer AJCC v8Stage II Lung Cancer AJCC v8Stage IIA Lung Cancer AJCC v8Stage IIB Lung Cancer AJCC v8Stage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8
NCT04183218Mayo Clinic24
Completed
Not Applicable
Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Breast Cancer PatientsCardiotoxicity
NCT04790266Oncology Institute of Southern Switzerland150
Completed
Not Applicable
Early Detection of Cardiovascular Changes After Radiotherapy for Breast CancerBreast Cancer Female
NCT03297346Institut de Radioprotection et de Surete Nucleaire250
Recruiting
Not Applicable
Cardiac Magnetic Resonance for Early Detection of Chemotherapy or Radiation Therapy Induced Cardiotoxicity in Breast Cancer (CareBest)Chemotherapy Induced Cardiotoxicity
NCT03301389Yonsei University2,000
Terminated
Not Applicable
Cardiotoxic Effects of Chemotherapy in Patients With Sarcomas: A Two and Three-dimensional Echocardiographic Speckle Tracking Imaging StudySarcoma
NCT06511388Mayo Clinic400